Apogee Therapeutics Logo
US03770N1019
APGE

Apogee Therapeutics

Prognose

Analytikernes gennemsnitlige kursmål er 118,39 € (+1,54 %). Medianen er 123,03 € (+5,52 %).

Køb
  2
Behold
  12
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Apogee Therapeutics reaches record high at $134.89

    Apogee Therapeutics' stock reached a record high of $134.89, representing a year-to-date gain of 256.92%. InvestingPro notes the stock may appear overvalued at this level and that its fair-value estimate is substantially lower. Apogee has more cash than debt but was unprofitable over the past twelve months. Shareholders approved AbbVie's acquisition, which values the company at $10.9 billion ($135.11 per share) and prompted analyst downgrades and adjusted price targets. » Mere på de.investing.com


  • Apogee Therapeutics reaches record high at $134.47 ahead of takeover by AbbVie

    Apogee Therapeutics shares rose to an all-time high of $134.47 and show a year-to-date return of around 270% with a market capitalization of $10.08 billion. AbbVie announced an acquisition agreement at $135.11 per share, valuing Apogee at about $10.9 billion, while InvestingPro and RSI indicators point to overvaluation and overbought conditions. After the announcement, Mizuho and UBS downgraded the stock from buy to neutral, while RBC raised its price target to $97; Apogee also closed R&D agreements with Paragon Therapeutics and appointed new directors. » Mere på de.investing.com


  • Apogee Therapeutics sold by Baron Capital after AbbVie agrees $135.11-per-share buyout

    Baron Health Care Fund sold its position in Apogee Therapeutics following AbbVie's announced acquisition of Apogee for $135.11 per share, a 49.5% premium to the prior close. The fund cited Apogee as a key contributor to its biotechnology stock selection during Q2 and reported overall quarterly gains. Apogee shares have risen sharply over the past year and the deal values the company at roughly $10.11 billion. » Mere på finance.yahoo.com


  • Apogee Therapeutics reaches record high of $134.34

    Shares of Apogee Therapeutics rose to an all-time high of $134.34, about 243% above last year; market capitalization is roughly $10.05 billion. AbbVie announced a takeover agreement at $135.11 per share, valuing the company at about $10.9 billion, after which analysts at Mizuho and UBS downgraded the stock to "Neutral" and cited price targets around $135. Additional developments: a partnership with Paragon Therapeutics to develop an IL-31R antibody, an RBC price target of $97, and the move of zumilokibart into phase III trials. » Mere på de.investing.com


  • Apogee Therapeutics reaches record high of $133.88 after takeover agreement with AbbVie

    Apogee Therapeutics' stock rose to a record high of $133.88, bringing market capitalization to about $10.02 billion. InvestingPro rates the stock as overvalued versus its fair value and notes an overbought RSI, despite strong performance (+250% over the past year). AbbVie announced a definitive takeover agreement at $135.11 per share (around $10.9 billion), after which several analysts downgraded their ratings to neutral and set price targets near $135. Additionally, Apogee announced collaboration agreements with Paragon Therapeutics to develop antibodies against the interleukin-31 receptor, and confirmed board elections and approved shareholder proposals. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde Apogee Therapeutics en omsætning på 0 € og et nettoresultat på -75,23 mio. €

(EUR) juni 2026
YoY
Omsætning 0 -
Bruttofortjeneste 0 -
Nettoresultat -75,23 mio. 34,15 %
EBITDA -73,42 mio. 31,86 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
7,66 mia. €
Antal aktier
62,2 mio.
Højeste/laveste i 52 uger
123,11 € - 32,25 €
Udbytte Nej
Beta
0,34
P/E (PE Ratio)
-31,12
PEG (PEG Ratio)
6,57
K/I (PB Ratio)
8,53
P/S (PS Ratio)
0,00

Virksomhedsprofil

Apogee Therapeutics, Inc. drives sin virksomhed gennem et datterselskab og er et bioteknologiselskab, der udvikler biologiske lægemidler til behandling af atopisk dermatitis (AD), kronisk obstruktiv lungesygdom (KOL) og beslægtede inflammatoriske og immunologiske indikationer. Selskabet udvikler primært APG777, en subkutan (SQ) monoklonal antistof (mAb) med forlænget halveringstid til AD; og APG808, en SQ mAb med forlænget halveringstid til KOL. Dets tidligere udviklingsprogrammer omfatter APG990, en SQ mAb med forlænget halveringstid til behandling af AD; og APG222, SQ-antistoffer med forlænget halveringstid til AD. Selskabet blev grundlagt i 2022 og har hovedkontor i Waltham, Massachusetts.

Navn
Apogee Therapeutics
CEO
Michael Thomas Henderson
Hjemsted Waltham, ma
USA
Websted
Branche
Fødevarer
Børsnotering
14.07.2023
Medarbejdere 261

Tickersymboler

Børs Symbol
NASDAQ
APGE
🍪

Parqet  bruger cookies. Læs mere